Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy

Yingyao Chen and colleagues examine what can be learnt from China’s approach to funding expensive high technology medicines with uncertain long term benefit

Detalles Bibliográficos
Autores principales: Chen, Yingyao, Dong, Hengjin, Wei, Yan, Yang, Yi, Ming, Jian, Yu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2023
Materias:
Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266439/
https://www.ncbi.nlm.nih.gov/pubmed/37321628
http://dx.doi.org/10.1136/bmj-2022-069963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266439/
https://www.ncbi.nlm.nih.gov/pubmed/37321628
http://dx.doi.org/10.1136/bmj-2022-069963

Ejemplares similares